The goal of our study is to compare the cost-effectiveness of serplulimab plus chemotherapy with chemotherapy alone for untreated, PD-L1-positive advanced ESCC patients in the Chinese healthcare system. The gene discussed is CD274; the disease is esophageal squamous cell carcinoma.